US drug marketing: how does promotion correspond with health value?

@article{Greenway2017USDM,
  title={US drug marketing: how does promotion correspond with health value?},
  author={Tyler S. Greenway and Joseph S. Ross},
  journal={British Medical Journal},
  year={2017},
  volume={357}
}
Tyler Greenway and Joseph S Ross assess the effectiveness, usefulness, and affordability of the drugs that get the heaviest promotion 
Medicines Information and the Regulation of the Promotion of Pharmaceuticals
TLDR
This review examines how the promotion of pharmaceuticals directly affects the prescribing and use of medicines and looks in greater detail at promotion techniques aimed at prescribers, such as sales representatives, pharmaceutical advertisements in medical journals andUse of key opinion leaders.
The relation between promotional spending on drugs and their therapeutic gain: a cohort analysis.
  • J. Lexchin
  • Medicine, Political Science
    CMAJ open
  • 2017
TLDR
Nearly all the money spent on promotion in each of the 3 years went to drugs with little to no therapeutic gain, calling into question whether doctors should read journal advertisements or see sales representatives to acquire information about important medical therapies.
Polypharmacy, the Good Prescribing Continuum, and the Ethics of Deprescribing
TLDR
This research presents a novel and scalable approach called “informed consent” to provide real-time, scalable, and efficient care to patients with complex medical needs in Worcester.
Information and promotional strategies by pharmaceutical companies for clinicians
TLDR
The effects of prescriptions stimulated by pharmaceutical industry promotional interactions with prescribers on clinical patient outcomes are assessed and whether these listed factors are effect modifiers are explored.
Industry Payments to Rheumatologists Ought to Be Going Down, Not Up
TLDR
Findings are in line with similar reports from other medical and surgical specialties, and highlight the overarching concern regarding the ability of industry payments to adversely affect care quality within the specific context of rheumatology practice.
A proposed taxonomy for population-level prescription use patterns.
TLDR
The authors hope the proposed taxonomy will inform discussion of prescription drug value by providing estimates of population impact, especially the balance of anticipated benefit and harm.
Approvals and Timing of New Formulations of Novel Drugs Approved by the US Food and Drug Administration Between 1995 and 2010 and Followed Through 2021
This cross-sectional study examines whether new formulations of brand-name novel drugs were associated with novel drugs’ sales and/or therapeutic value as well as characterizes new formulations’
Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015
TLDR
This cross-sectional study of the Disclosure UK database found that in 2015, 4028 health care organizations received US $72 110 156.6 from 100 companies, meaning more policy attention is needed to disclose organizational conflicts of interests, particularly in areas of the health care system with a high concentration of industry payments.
Medical Marketing in the United States, 1997-2016
TLDR
The marketing of prescription drugs, disease awareness campaigns, health services, and laboratory tests and the related consequences and regulation in the United States over a 20-year period (1997-2016) is reviewed.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Teaching clinicians about drugs--50 years later, whose job is it?
  • J. Avorn
  • Political Science, Medicine
    The New England journal of medicine
  • 2011
In 1961, U.S. legislation transformed prescription drug approval and use. One question it raised was how and by whom information about drugs should be evaluated and communicated to physicians. Half a
The Physician Payments Sunshine Act--Two Years of the Open Payments Program.
Through the Open Payments program (under the Physician Payments Sunshine Act), the Centers for Medicare and Medicaid Services aims to produce more informed consumers, greater understanding of
Industry support of physician education in the USA
TLDR
The role that industry plays in the education of physicians is reviewed, including analyses of initial data from the Open Payments programme, and current international transparency efforts and existing gaps in transparency of US industry–medicine relationships are discussed.
Pharmaceutical Industry-Sponsored Meals and Physician Prescribing Patterns for Medicare Beneficiaries.
TLDR
To study the association between physicians' receipt of industry-sponsored meals, which account for roughly 80% of the total number of industry payments, and rates of prescribing the promoted drug to Medicare beneficiaries, industry payment data and Medicare prescribing records recently became publicly available.
Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
TLDR
Industry payments to physicians are associated with higher rates of prescribing brand-name statins, and as the United States seeks to rein in the costs of prescription drugs and make them less expensive for patients, these findings are concerning.
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.
TLDR
It is found that trends in NME approvals were largely driven by addition-to-class, or "me too," drug approvals, while first-in-class approvals remained fairly steady over the study period.
Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study
TLDR
Payments to specialists and payments for speaker and consulting fees were predominantly associated with greater regional prescribing of marketed drugs than payments to non-specialists or payments for food and beverages, gifts, or educational materials.
Does Exposure to Conflict of Interest Policies in Psychiatry Residency Affect Antidepressant Prescribing?
TLDR
The results suggest that COI policies can help inoculate physicians against persuasive aspects of pharmaceutical promotion, and further research should assess whether these policies affect other drug classes and physician specialties similarly.
Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis
TLDR
Exposure to a gift restriction policy during medical school was associated with reduced prescribing of two out of three newly introduced psychotropic medications.
Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota.
TLDR
The Vermont and Minnesota laws requiring disclosure of payments do not provide easy access to payment information for the public and are of limited quality once accessed.
...
...